1 enrolling by invitation. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Astrazeneca: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) Durvalumab, Olaparib - Small Cell Lung Carcinoma | Phase 2 | Enrolling by invitation | University of Cologne | 29 | 2024-10-09 | 2025-05-20 |
durvalumab (1) · olaparib (1)
Germany (1)